多配体聚糖结合蛋白在乳腺癌及其他恶性肿瘤中作用的研究进展  

Research progress of the contribution of syndecan binding protein to the development of breast cancer and other malignancies

作　　者：钱晓龙[1] 郭晓静[1] 

机构地区：[1]天津医科大学肿瘤医院乳腺病理研究室,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,乳腺癌防治教育部重点实验室,天津市300060

出　　处：《中国肿瘤临床》2015年第11期576-579,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学青年科学基金项目(编号:81302292)资助~~

摘　　要：多配体聚糖结合蛋白(SDCBP)是一种将多配体聚糖介导的信号与细胞骨架联系起来的分子,与多种恶性肿瘤的进展密切相关。乳腺癌是一种包含多种亚型的异质性疾病,具有不同的分子表型、临床特征以及对治疗的不同反应。为对那些缺乏有效个体化治疗手段的乳腺癌特别是三阴性乳腺癌和内分泌治疗耐药的乳腺癌,及其他恶性肿瘤的靶向性治疗提供新的思路,本文将就SDCBP在乳腺癌及其他恶性肿瘤中参与的信号转导途径和发挥的作用进行综述。Syndecan binding protein （SDCBP） has been identified as a molecule linking syndecan-mediated signaling to the cyto- skeleton; SDCBP has also contributed to the development of many malignancies, including breast cancer. Breast cancer is a heteroge- neous disease encompassing multiple subgroups with different molecular signatures, clinical characteristics, and responses to therapies. This article reviews the pathways of SDCBP interaction and its functions in the tumor progression of breast cancer and other malignan- cies to provide novel ideas of targeted therapies for breast cancers, particularly triple-negative and endocrine therapy-resistant breast cancers and other malignancies, that lack effective individualized treatments.

关 键 词：多配体聚糖结合蛋白 乳腺癌 黑色素瘤 信号转导 

分 类 号：R730.2[医药卫生—肿瘤]